Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial

[1]  L. Carey,et al.  P53 mutation and differential response to neoadjuvant chemotherapy in women with locally advanced breast cancer: Results from the I-SPY trial (CALGB 150007/1500012 and ACRIN 6657). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  C. Perou,et al.  TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab , 2012, Breast Cancer Research and Treatment.

[3]  D. Berry,et al.  p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905) , 2011, Clinical Cancer Research.

[4]  Tanja Cufer,et al.  TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. , 2011, The Lancet. Oncology.

[5]  W. Wang,et al.  Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case–control study , 2011, Breast Cancer Research and Treatment.

[6]  A. Thompson,et al.  p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients , 2011, Breast Cancer Research.

[7]  Y. Qi,et al.  Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers , 2011, Clinical Cancer Research.

[8]  A. Ruíz,et al.  Adjuvant docetaxel for high-risk, node-negative breast cancer. , 2010, The New England journal of medicine.

[9]  Z. Szallasi,et al.  Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  V. Rotter,et al.  Mutant p53 gain-of-function in cancer. , 2010, Cold Spring Harbor perspectives in biology.

[11]  G. Viale,et al.  Overall Survival Benefit for Sequential Doxorubicin-Docetaxel Compared to Concomitant Doxorubicin and Docetaxel in Node-Positive Breast Cancer. 8-Yr. Results of the Breast International Group (BIG) 2-98 Phase III Adjuvant Trial. , 2009 .

[12]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[13]  I. Ellis,et al.  Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial , 2009, The Lancet.

[14]  C. Prives,et al.  Blinded by the Light: The Growing Complexity of p53 , 2009, Cell.

[15]  R. Gelber,et al.  Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. , 2008, Journal of the National Cancer Institute.

[16]  M. Olivier,et al.  Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.

[17]  C. Sotiriou,et al.  p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Hongjuan Zhao,et al.  TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer , 2007, Breast Cancer Research.

[19]  M. Espié,et al.  Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen , 2007, PLoS medicine.

[20]  T. Delozier,et al.  Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Charles M Perou,et al.  Gene expression patterns associated with p53 status in breast cancer , 2006, BMC Cancer.

[22]  J. Bergh,et al.  The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  U. Dafni,et al.  Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Ahluwalia,et al.  Adjuvant docetaxel for node-positive breast cancer. , 2005, The New England journal of medicine.

[26]  J. Bryant,et al.  Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  L. Strong,et al.  Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.

[28]  A. Inga,et al.  Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  S. Kato,et al.  Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Richard L Schilsky,et al.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Espié,et al.  Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer , 2002, Oncogene.

[32]  H. Bonnefoi,et al.  p53 as a potential predictive factor of response to chemotherapy: feasibility of p53 assessment using a functional test in yeast from trucut biopsies in breast cancer patients , 2002, British Journal of Cancer.

[33]  C. Nam,et al.  Is body mass index the prognostic factor in breast cancer?: a meta-analysis. , 2001, Journal of Korean medical science.

[34]  T. Aas,et al.  Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. , 2001, Cancer research.

[35]  B. Iacopetta,et al.  Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  C Caldas,et al.  Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis , 1999, British Journal of Cancer.

[37]  J N Weinstein,et al.  Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.

[38]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[39]  D. Larsimont,et al.  Prognostic and predictive value of TP 53 mutations in node-positive breast cancer patients treated with anthracycline-or anthracycline / taxane-based adjuvant therapy : results from the BIG 02-98 phase III trial , 2012 .

[40]  R. Gelber,et al.  The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial , 2009, Breast Cancer Research and Treatment.

[41]  C. Bao.  Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197 , 2009 .

[42]  Xueri Li,et al.  Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients:The FNCLCC PACS 01 Trial , 2009 .

[43]  C. Criscitiello,et al.  Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  A. Børresen-Dale,et al.  Prognostic and Predictive Value of TP53 Mutations in Human Cancer , 2007 .

[45]  P. Hainaut,et al.  25 years of p53 research , 2005 .

[46]  S. Bull,et al.  The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  M. Gnant,et al.  TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  G. Demers,et al.  Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis , 1996, Nature Medicine.